Table 3.
Clinical characteristics of the 8 cases of NVP-induced liver injury. *HLAB5701 tested absent
| Pt 1 | Pt 2 | Pt 3 | Pt 4 | Pt 5 | Pt 6 | Pt 7 | Pt 8 | |
|---|---|---|---|---|---|---|---|---|
| HCV coinfection | no | yes | yes | yes | yes | no | yes | yes |
| ARV status | Experienced | Experienced | Experienced | Experienced | Naive | Experienced | Experienced | Experienced |
| Concomitant ARV | d4T + 3TC | d4T + 3TC | ABC* + 3TC | AZT + 3TC | AZT + 3TC | d4T + ddi | AZT + 3TC | d4T + ddi |
| NVP exposure before treatment interruption (days) | 28 | 61 | 29 | 28 | 58 | 28 | 50 | 38 |
| Concomitant medication | none | none | Vitamin D and folinic acid | none | Phenobarbital and alprazolam | none | None | Folinic acid |
| Symptoms | Nausea and severe weakness | none | Nausea | none | Weakness | none | Nausea | None |
| Required hospitalization | yes | no | yes | no | no | no | no | no |
| Outcome | Recovered without sequelae | Recovered without sequelae | Recovered without sequelae | Recovered without sequelae | Recovered without sequelae | Recovered without sequelae | Recovered without sequelae | Recovered without sequelae |
| RUCAM | Probable | Probable | Possible | Probable | Possible | Probable | Probable | Possible |
Abbreviations: Pt Patient, HCV Hepatitis C virus, ARV Antiretroviral, d4T Stavudine, 3TC Lamivudine, ABC Abacavir, AZT Zidovudine, ddi Didanosine, RUCAM Roussel Uclaf Causality Assessment Method